Welcome to our dedicated page for TRINITY BIOTECH PLC SEC filings (Ticker: TRIB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trinity Biotech plc SEC filings document foreign-issuer reports furnished on Form 6-K for its diagnostics, diabetes management, and health technology operations. The filings record announcements tied to Premier Hb9210 diabetes testing, CGM+ biosensor development, EpiCapture prostate cancer diagnostics, North America commercial operations, trading updates, and the Comprehensive Transformation Plan.
The company’s filings also disclose ADS and ordinary-share capital matters, including a standby equity purchase agreement; credit-agreement waivers and covenant deferrals; Nasdaq listing-compliance notices for the ADSs; and incorporation by reference into Form S-8 registration statements. These records describe the formal reporting framework for Trinity Biotech as a foreign private issuer using Form 20-F reporting status.
Trinity Biotech plc is registering a post-effective Form F-3 to convert its prior Form F-1 and to register for resale up to 167,950,998 ADSs, representing 3,359,019,957 Ordinary Shares, by Perceptive Credit Holdings II, L.P. and Perceptive Credit Holdings III, L.P. (together, "Perceptive").
The ADSs are issuable pursuant to conversion rights and a convertible note described as the "Conversion Documents." Conversions are subject to a 9.9% Beneficial Ownership Cap and a minimum floor conversion price of $0.5061 per ADS. The company will not receive cash proceeds from Selling Shareholder resales; conversions reduce outstanding Conversion Obligations.
Trinity Biotech named Jerry Lydon Head of North America Commercial Operations as its diagnostics business shifts from restructuring toward building revenue momentum and profitability on a leaner operating base. His role covers the North America portfolio and the New York reference lab, including pipeline products such as EpiCapture and PrePsia.
The company reported Q4 2025 revenue of $11.1 million, down from $15.9 million a year earlier, mainly due to disruptions in global HIV testing funding and manufacturing transitions. Despite lower sales, Q4 gross margin improved from 30.8% to 35.2%, though net loss widened slightly to $17.5 million, including a one‑off $10.0 million IFRS charge linked to modified Perceptive financing.
For 2025, revenue fell to $43.8 million from $61.6 million, with point‑of‑care and haemoglobin sales both declining during the transformation and market disruption. Full‑year gross margin rose from 34.8% to 38.6%, and net loss was $37.4 million. Adjusted EBITDA improved to a loss of $5.9 million versus a $11.3 million loss in 2024, reflecting early financial benefits from the Comprehensive Transformation Plan, including outsourced HIV manufacturing now scaled and expected to support margins from Q2 2026.
Trinity Biotech plc’s major creditor group, led by Perceptive Advisors, has updated its ownership and financing terms. The reporting persons now show beneficial ownership of 3,424,019,957 Class A Ordinary Shares, representing 9.9% of the class, largely through warrants and convertible instruments.
On April 30, 2026, Perceptive Credit Holdings III, L.P. agreed a Limited Waiver and Third Amendment to Trinity Biotech’s credit agreement, waiving certain financial covenant non-compliance and providing an additional $2.5 million term loan. At the same time, the senior Convertible Note was amended to raise the maximum principal amount convertible into ADSs from $60,000,000 to $72,500,000 and to reduce the minimum conversion price from $1.03 to $0.5061 per ADS. Related changes were made to the Conversion Rights Agreement. These securities are subject to a Beneficial Ownership Cap limiting how many shares the group can beneficially own at any time.
Trinity Biotech plc files its annual Form 20-F for the year ended December 31, 2025, highlighting ongoing losses, high leverage and material risk factors. The company reported net losses of US$37.4 million in 2025 and US$31.8 million in 2024 and negative operating cash flows in both years.
Trinity carries total indebtedness of about US$141.3 million, including a senior secured Term Loan to Perceptive and a junior convertible note to MiCo, with US$108.0 million of variable‑rate debt accruing at roughly 12.75% annually. Management states that continuation as a going concern depends on generating operating cash and obtaining additional financing while executing a transformation plan focused on manufacturing consolidation, cost reduction and expansion into biosensor and continuous glucose monitoring products.
Trinity Biotech plc director Ronan O'Caoimh has filed an initial ownership report showing significant direct stakes in the company. He reports holding 486,208 ADS as of the filing date. In addition, he holds multiple ADS option awards with exercise prices of $13.70, $14.50, $3.80 and $2.80 per ADS, with expiration dates ranging from 2026 to 2031, providing potential future rights to acquire additional ADS over several years.
Trinity Biotech plc director John Gillard filed an amended initial insider report detailing his existing holdings in American Depositary Share (ADS) options and ADSs. The filing shows multiple option grants, including ADS options over 40,000 shares at an exercise price of $5.70 expiring on December 19, 2029, and ADS options over 43,750 shares at an exercise price of $2.40 expiring on December 11, 2030. It also notes ADS options over 7,500 shares at an exercise price of $13.45 expiring on October 23, 2027, along with direct ownership of 10,000 ADSs. The report records holdings only and does not show any new purchases or sales.
TRINITY BIOTECH PLC filed a Form 3 to report that Paul Murphy, the company’s Interim CFO, is now an insider required to report holdings and future trades in the company’s securities. The filing lists no initial share or option positions and shows no buy, sell, or exercise activity.
Trinity Biotech plc director John Paul Tivnan has filed a Form 3 insider ownership report for ticker TRIB. The data provided show no reported transactions, with buy, sell, exercise, gift, tax withholding, and restructuring share counts all at zero, indicating purely a baseline regulatory filing.
TRINITY BIOTECH PLC director John Gillard filed an initial statement of beneficial ownership, showing holdings of ADS options and common ADS. The filing lists multiple option grants over TRIB ADS with exercise prices between $2.40 and $13.45, plus 10,000 ADS held directly.
Trinity Biotech plc director Andrew Omidvar filed an initial Form 3 reporting holdings of ADS options. The options have an exercise price of $2.80 per ADS and expire on February 2, 2031. Multiple option tranches cover underlying ADS amounts of 7,292 and 2,917, with various future exercise dates extending into 2027.